SHK could overcome TKI resistance in CML cells by inducing necroptosis via activation of receptor-interacting protein kinase 1 (RIPK1)/RIPK3/mixed lineage kinase domain-like protein (MLKL) signaling both in vitro and in vivo (Huang et al., 2020). Here, MLKL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.